Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 10Urogenital Neoplasms 1Prostatic Diseases 1Prostate Cancer Metastatic 1Oligometastatic Prostate Cancer (OMPC) 1Neoplasm Metastasis 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Biochemically Recurrent Prostate Carcinoma 1

Interventions

padeliporfin 5darolutamide 3Pluvicto 3gallium 68 PSMA-11 2enzalutamide 2apalutamide 2Radiotherapy 2Nivolumab 2Androgen Antagonists 2Abiraterone Acetate 2talazoparib 1sipuleucel-T 1palladium-bacteriopheophorbide 1onapristone 1olaparib 1niraparib 1luprolide acetate gel depot 1ixabepilone 1gedatolisib 1abiraterone 1Therapeutics 1Tamsulosin 1Surveys and Questionnaires 1Standard of Care 1Robotic Surgical Procedures 1Prostate-Specific Antigen 1Prednisone 1Paclitaxel 1Oxygen 1Nitrous Oxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Diseases × Lutetium-177 × Genitourinary × Clear all
NCT05413850 2026-05-14

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd

Phase 1/2 Recruiting
82 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡